Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant  

作　　者：Wanbo Tai Benjie Chai Shengyong Feng Xinyu Zhuang Jun Ma Mujia Pang Lin Pan Zi Yang Mingyao Tian Gong Cheng 

机构地区：[1]Institute of Infectious Diseases,Shenzhen Bay Laboratory,Shenzhen,Guangdong,China [2]Tsinghua-Peking Joint Center for Life Sciences,School of Medicine,Tsinghua University,Beijing,China [3]Changchun Veterinary Research Institute,Chinese Academy of Agricultural Sciences,Changchun,China

出　　处：《Signal Transduction and Targeted Therapy》2022年第7期2135-2137,共3页信号转导与靶向治疗（英文）

基　　金：supported by the Emergency Key Program of Guangzhou Laboratory(EKPG21-33);the National Natural Science Foundation of China(32188101,32100755,81730063,81961160737 and 31825001);the National Key Research and Development Plan of China(2021YFC2300200,2020YFC1200104 and 2017ZX10304402).

摘　　要：Dear Editor,The COVID-19 pandemic has had a devastating effect on global health,resulting in over 6.2 million deaths worldwide.Continuous emergence of adaptive mutations of SARS-CoV-2 alters its pathogenicity and transmissibility,and renders its resistance to current vaccines and antiviral drugs.1 A new variant named Omicron discovered initially in South Africa has recently been proposed as a variant of concern(VOC)by the World Health Organization,because of its high transmissibility and resistance to current vaccines and therapeutic antibodies.2 Therefore,development of vaccines against prevalent variants including Omicron is urgently needed for COVID-19 prevention.

关 键 词：RENDER resistance initially 

分 类 号：R373.19[医药卫生—病原生物学]